You never know what you'll get when a company goes public. Some start fast and then die off faster. Others have a slow and steady rise to the top. And of course, some take off and provide investors with massive returns in a short period

In 2021, there were 1,035 IPOs. So, when you consider that there were only 181 last year, it's easy to see there was a massive slowdown. However, that doesn't mean there were no opportunities to make money.

Of the 181 companies, 88 have generated a positive return since their IPO date. Of that group, two stand out from the crowd: Belite Bio and Arcellx.

Don’t Miss:

• Until 2016 it was illegal for retail investors to invest in high-growth startups. Thanks to changes in federal law, this Kevin O’Leary-backed startup lets you become a venture capitalist with $100.
• The VC firm that backed Apple before its IPO in 1980 is focusing on AI — Here's how you can do the same with $1,000.

Belite Bio

Belite Bio is a biopharmaceutical company focused on developing drugs for degenerative eye conditions and liver diseases. The company’s main product, LBS-008 (Tinlarebant), is a daily oral tablet aimed at treating vision loss in conditions like Stargardt disease and geographic atrophy. 

Additionally, Belite Bio is working on LBS-009, an oral medication for a range of liver issues and metabolic disorders that is currently in the preclinical trial stage. 

Founded in 2016, the company works as a subsidiary of Lin Bioscience International Ltd. and is headquartered in San Diego, California.

Since its IPO date on Apr. 29, 2022, the stock has returned 568.33%. 

The stock closed at $10.59 on its first day and is currently trading at $38.80. A $1,000 investment at that time would be worth approximately $3,663 today. 

Trending: With returns as high as 300%, it’s no wonder this asset is the investment choice of many billionaires. Uncover the secret.

Arcellx

Arcellx. is a biotech firm advancing immunotherapies for cancer and other serious diseases. The company’s flagship development, CART-ddBCMA, is in phase 2 trials for treating advanced multiple myeloma. Further projects include ACLX-001 for multiple myeloma and ACLX-002 and ACLX-003 targeting acute myeloid leukemia and myelodysplastic syndrome. 

With a focus on solid tumor treatments, Arcellx has partnered with Kite Pharma for the co-development and sale of its lead therapy. Originating as Encarta Therapeutics (2014), the company rebranded in 2016 and is based in Gaithersburg, Maryland. 

Since its IPO date on Feb 4, 2022, the stock has returned 218.27%.

The stock closed at $16.80 on its first day and is currently trading at $46.09. A $1,000 investment at that time would be worth approximately $2,743 today. 

If you want to invest in startups that could IPO in the future, visit StartEngine's online crowdfunding platform. 

Read Next:

• Discover why high-profile names like Leonard Dicaprio are turning to diamond assets and how you can get involved with just $100.
• Many NBA players, including LeBron James, have ventured into fine wine investments as an alternative asset. Now you can too with just $25.